Quick Answer
ClearPoint Neuro, Inc. reported Total Revenue of $36.97 million for fiscal year 2025.
ClearPoint Neuro, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $36.97M +17.8% |
$31.39M +31.0% |
$23.95M +16.6% |
$20.55M +26.1% |
$16.30M +27.0% |
$12.83M +14.4% |
| Net Income | -$25.54M -35.0% |
-$18.91M +14.4% |
-$22.09M -34.4% |
-$16.43M -14.1% |
-$14.41M -112.5% |
-$6.78M -22.4% |
| Diluted EPS | -$0.90 -28.6% |
-$0.70 +22.2% |
-$0.90 -32.4% |
-$0.68 +1.4% |
-$0.69 | — |
| Total Assets | $97.75M +149.4% |
$39.19M -8.1% |
$42.66M -23.1% |
$55.49M -15.4% |
$65.58M +122.2% |
$29.52M +147.5% |
| Cash and Equivalents | $45.92M +128.4% |
$20.10M -13.1% |
$23.14M -16.2% |
$27.61M -49.0% |
$54.11M +169.2% |
$20.10M +252.9% |
| Stockholders Equity | $28.02M +10.4% |
$25.39M +19.9% |
$21.17M -42.6% |
$36.89M -24.4% |
$48.79M +1952.5% |
$2.38M -48.2% |
| R&D Expense | $13.90M +12.1% |
$12.39M +5.8% |
$11.71M +7.5% |
$10.89M +17.4% |
$9.28M +98.1% |
$4.69M +66.8% |
| Operating Income | -$24.16M -22.4% |
-$19.73M +12.1% |
-$22.45M -37.4% |
-$16.33M -22.1% |
-$13.37M -115.0% |
-$6.22M -35.4% |
| Gross Profit | $22.69M +18.7% |
$19.12M +40.5% |
$13.61M +0.6% |
$13.53M +21.6% |
$11.12M +22.0% |
$9.12M |
| Shares Outstanding | 29.37M +6.3% |
27.62M +12.0% |
24.65M +0.3% |
24.58M +3.9% |
23.67M +38.8% |
17.05M +11.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $8.86M | +9.1% | -3.8% |
| Revenue (ASC 606) | September 30, 2022 | $5.15M | +12.5% | +12.5% |
| Net Income | September 30, 2025 | -$5.89M | -18.4% | -0.9% |
| Diluted EPS | September 30, 2025 | -$0.21 | -16.7% | +0.0% |
| Total Assets | September 30, 2025 | $60.36M | +50.2% | -4.0% |
| Cash and Equivalents | September 30, 2025 | $38.22M | +77.2% | -8.0% |
| Long-Term Debt | September 30, 2020 | $822.0K | — | +37.2% |
| Stockholders Equity | September 30, 2025 | $15.87M | -45.3% | -19.6% |
| R&D Expense | September 30, 2025 | $3.45M | +4.1% | -9.8% |
| Operating Income | September 30, 2025 | -$5.28M | -2.3% | +7.1% |
| Gross Profit | September 30, 2025 | $5.60M | +15.5% | +0.8% |
| Shares Outstanding | September 30, 2025 | 28.43M | +3.0% | +0.0% |
- ClearPoint Neuro, Inc. reported Total Revenue of $36.97 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed an increase of +17.8% in Total Revenue compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Net Income of -$25.54 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed a decrease of -35.0% in Net Income compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Diluted EPS of $0.90 per share (loss) for fiscal year 2025.
- ClearPoint Neuro, Inc. showed a decrease of -28.6% in Diluted EPS compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Total Assets of $97.75 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed an increase of +149.4% in Total Assets compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Cash and Equivalents of $45.92 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed an increase of +128.4% in Cash and Equivalents compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Stockholders Equity of $28.02 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed an increase of +10.4% in Stockholders Equity compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported R&D Expense of $13.90 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed an increase of +12.1% in R&D Expense compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Operating Income of -$24.16 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed a decrease of -22.4% in Operating Income compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Gross Profit of $22.69 million for fiscal year 2025.
- ClearPoint Neuro, Inc. showed an increase of +18.7% in Gross Profit compared to the prior fiscal year.
- ClearPoint Neuro, Inc. reported Shares Outstanding of 29.37 million shares for fiscal year 2025.
- ClearPoint Neuro, Inc. showed an increase of +6.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: